OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting

Author's Avatar
Dec 03, 2018
Article's Main Image

CG-806 Pan-FLT3/Pan-BTK Inhibitor Exhibits Favorable Safety Profile and Unexpected Potency on Primary Cells from B-cell Cancer Patients and AML Patients